东北制药
(000597)
| 流通市值：81.86亿 | | | 总市值：82.91亿 |
| 流通股本：14.09亿 | | | 总股本：14.27亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 3,852,608,126.41 | 1,947,277,598.78 | 7,502,554,909.23 | 6,133,512,515.79 |
| 营业收入 | 3,852,608,126.41 | 1,947,277,598.78 | 7,502,554,909.23 | 6,133,512,515.79 |
| 二、营业总成本 | 3,627,698,065.72 | 1,828,004,577.99 | 6,888,697,612.66 | 5,783,158,351.88 |
| 营业成本 | 2,515,169,386.75 | 1,283,000,859.34 | 4,596,466,279.52 | 4,015,426,869.88 |
| 税金及附加 | 36,400,771.14 | 17,337,637.15 | 77,341,554.24 | 53,452,496.49 |
| 销售费用 | 625,114,853.86 | 307,273,222.11 | 1,381,892,380.61 | 1,047,384,162.17 |
| 管理费用 | 382,332,472.58 | 196,073,967.25 | 741,452,499.9 | 619,708,039.04 |
| 研发费用 | 71,797,472.56 | 31,999,540.39 | 117,763,982.51 | 53,424,342.8 |
| 财务费用 | -3,116,891.17 | -7,680,648.25 | -26,219,084.12 | -6,237,558.5 |
| 其中:利息费用 | 24,069,106.24 | 11,720,485.46 | 64,533,460.27 | 53,028,998.09 |
| 其中:利息收入 | 46,496,461.42 | 24,526,792.86 | 128,628,643.84 | 101,229,361.69 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 2,871,681.33 | 1,350,929.69 | 5,160,420.26 | 3,443,648.35 |
| 资产处置收益 | 181,512.23 | 8,990.07 | 6,192,436.61 | 6,653.37 |
| 资产减值损失(新) | -90,837,948.21 | -64,439,253.74 | -125,566,328.87 | -81,626,706.85 |
| 信用减值损失(新) | -2,793,579.23 | -5,872,091.65 | 2,544,051.19 | -1,673,058.97 |
| 其他收益 | 59,793,951.43 | 25,452,646.61 | 75,573,520.7 | 65,858,411.31 |
| 四、营业利润 | 194,125,678.24 | 75,774,241.77 | 577,761,396.46 | 336,363,111.12 |
| 加:营业外收入 | 4,427,705.87 | 1,812,944.94 | 48,519,028.2 | 15,948,218.26 |
| 减:营业外支出 | 20,908,559.62 | 11,510,920.82 | 32,370,037.1 | 3,273,589.14 |
| 五、利润总额 | 177,644,824.49 | 66,076,265.89 | 593,910,387.56 | 349,037,740.24 |
| 减:所得税费用 | 53,382,106 | 30,704,850.96 | 170,628,065.67 | 128,984,177.81 |
| 六、净利润 | 124,262,718.49 | 35,371,414.93 | 423,282,321.89 | 220,053,562.43 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 124,262,718.49 | 35,371,414.93 | 423,282,321.89 | 220,053,562.43 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 129,178,610.43 | 36,321,572.23 | 409,848,498.88 | 207,968,558.91 |
| 少数股东损益 | -4,915,891.94 | -950,157.3 | 13,433,823.01 | 12,085,003.52 |
| 扣除非经常损益后的净利润 | 89,357,384.72 | 19,906,997.48 | 311,652,391.31 | 138,117,037.97 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.09 | 0.03 | 0.29 | 0.15 |
| (二)稀释每股收益 | 0.09 | 0.03 | 0.29 | 0.15 |
| 八、其他综合收益 | -167,773.2 | -58,468.97 | 629,692.33 | -451,414.36 |
| 归属于母公司股东的其他综合收益 | -168,568.1 | -58,741.05 | 632,527.83 | -453,406.95 |
| 九、综合收益总额 | 124,094,945.29 | 35,312,945.96 | 423,912,014.22 | 219,602,148.07 |
| 归属于母公司股东的综合收益总额 | 129,010,042.33 | 36,262,831.18 | 410,481,026.71 | 207,515,151.96 |
| 归属于少数股东的综合收益总额 | -4,915,097.04 | -949,885.22 | 13,430,987.51 | 12,086,996.11 |
| 公告日期 | 2025-08-27 | 2025-04-29 | 2025-04-03 | 2024-10-24 |
| 审计意见(境内) | | | 标准无保留意见 | |